Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The OUTREACH study: oncologists of German university hospitals in rotation on a palliative care unit-evaluation of attitude and competence in palliative care and hospice.
Biersching T, Schweda A, Oechsle K, Nauck F, Rosenbruch J, Schuler U, Hense J, Neukirchen M, Weber M, Junghanss C, Kramer T, Ostgathe C, Thuss-Patience P, Van Oorschot B, Teufel M, Schuler M, Bausewein C, Tewes M; OUTREACH Study Group. Biersching T, et al. Among authors: hense j. J Cancer Res Clin Oncol. 2023 Jul;149(7):2929-2936. doi: 10.1007/s00432-022-04131-w. Epub 2022 Jul 13. J Cancer Res Clin Oncol. 2023. PMID: 35831764 Free PMC article.
Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center.
Welt A, Bogner S, Arendt M, Kossow J, Huffziger A, Pohlkamp C, Steiniger H, Becker U, Alashkar F, Kohl M, Wiesweg M, Richly H, Hense J, Scheulen ME, Schuler M, Seeber S, Tewes M. Welt A, et al. Among authors: hense j. J Cancer Res Clin Oncol. 2020 Jun;146(6):1559-1566. doi: 10.1007/s00432-020-03184-z. Epub 2020 Mar 18. J Cancer Res Clin Oncol. 2020. PMID: 32189107 Free PMC article.
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
Kraskowski O, Stratmann JA, Wiesweg M, Eberhardt W, Metzenmacher M, Schmid KW, Herold T, Schildhaus HU, Darwiche K, Aigner C, Stuschke M, Laue K, Zaun G, Kasper S, Hense J, Sebastian M, Schuler M, Pogorzelski M. Kraskowski O, et al. Among authors: hense j. J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18. J Cancer Res Clin Oncol. 2023. PMID: 37198447 Free PMC article.
66 results